Quarterly report pursuant to Section 13 or 15(d)

Consolidated Condensed Interim Statement of Loss and Comprehensive Loss (Unaudited)

v3.5.0.2
Consolidated Condensed Interim Statement of Loss and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Expenses    
Research and development $ 732,729 $ 603,845
General and administrative 1,316,639 474,025
Operating expenses 2,049,368 1,077,870
Other loss (income)    
Change in fair value of stock option and derivative liabilities 225,688 539,446
Change in fair value of derivative liability due to change in warrant terms 21,565
Foreign exchange loss (gain) 15,324 (17,473)
Interest income (41) (20)
Other (income) loss 240,971 543,518
Net and comprehensive loss for the period 2,290,339 1,621,388
Computation of basic loss per share    
Net and comprehensive loss for the period 2,290,339 1,621,388
Series B Preferred stock dividend 307,298
Net and comprehensive loss available to common stockholders $ 2,597,637 $ 1,621,388
Basic loss per share $ 0.23 $ 0.15
Basic weighted average number of shares 11,301,989 10,620,469